VRNA - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Verona Pharma Second Quarter 2020 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. Earlier this morning, Verona Pharma issued a press release about its financial results for the three and six months ended June 30, 2020. A copy can be found in the Investor Relations tab on the corporate Web site www.veronapharma.com.

Before we begin, I would like to remind you that during today’s call statements about the company’s future expectations, plans, and prospects are forward-looking statements. based current are statements forward-looking on expectations. management's These of or nor involve other from known statements results, factors are unknown our and promises neither performance, claiming and expressed implied results, business. of actual clinical trials our impact and These and continuity expectations forward-looking and pandemic of materially on without limitations statements guarantees risks, cost may or COVID-XX including cause to achievements be that different important uncertainties, the the our the the with the status, enrollment, our management's Any statements as forward-looking of such date this call. represent estimate of the conference

While view the such future, update change. to the subsequent do forward-looking in any disclaims some if obligations to point elect company it may so its statements cause to even at events

recorded Executive turn over the ahead, Please I remain is reminder, for available call Chief year. call sir. to As a Zaccardelli, would Officer. this like David and will now go Dr. being to one

David Zaccardelli

to our call. me Medical of Rickard, Thank you, Officer; and Chief today's Kathy With Commercial. Mark President and Martin, today Chris Hahn, our Officer; Dr. Chief Financial our Vice everyone welcome are

Commercial Verona prepares few to appointing trials, our support be over the Phase instrumental Chris to financing Ensifentrine closing this of as Receiving COPD ENHANCE second Pharma as end Ensifentrine for will maintenance Martin, President, Vice an marked inhaled expertise by treatment and next including years productive COVID-XX, whose to X of new oversubscribed trials Verona patients objectives XXXX ensure in clinical a for become FDA organization. our quarter executed study year. to year. all Since is clinical on we package joining later to The with pivotal response begin a Phase accomplishments, our have $XXX Ensifentrine notice our was Phase Ensifentrine well-positioned to for X Phase to IND proceed highly nebulized several receiving progress this X X supportive the Pharma planned earlier to to quarter a a to year, million this ENHANCE for fund commercial-ready on trials

new million recent Chronic Disease, Perceptive the and market With secured Capital, proceeds which Foresite existing and Access Sphera, for was of unprecedented, supported Bioventures, raising validates our BioCapital, as investors Verona we for our program our Capital. shareholders, COPD in life believe Ensifentrine patients Samsara to by sheet into Management, a who We well new Capital, treatment benefit and Pulmonary potential Soleus gross times other of Ensifentrine is of our respiratory is Fairmount, we RA Advisors, for almost program with and understand expect XXXX. balance Biotechnology, Phase believe potential in Obstructive and Specifically, Ensifentrine the from capitalization, diseases. The Capital COPD. Pharma science clear financing, welcome COPD, fully-funded, support highly-experienced $XXX oversubscribed Acorn including a PBM X four our group financing strengthened,

Following the later financing to Phase FDA expect our we trials Phase package, X to clinical X end the our this of and commence year. response

put the have due potential X in monitor March, Phase Pressurized study the with of the we part related multi-dose and reduce likelihood Ensifentrine COVID-XX start Inhaler to strategies the impact the of the of Metered-Dose the of COPD. the to second pandemic, or a formulation postponed pMDI of of In on the place in continue timing we COVID-XX initiation, mitigation However, to delays.

XXXX. pleased the second in are that study of to first-half with of in results plan the of third quarter we start now expected the report part We to the XXXX

Ensifentrine, activity will life, lung dual as We safety and action of COPD Ensifentrine KOL you to that the mode anti-inflammatory well-served in leading patient. for about profile. favorable are clinical The millions in and as event regulatory treat an discussed quality of address function, systems, is beneficial community medical having with Ensifentrine Many for of in its the our the well well-validated encouraged a confident be by where treatment has potential important of pathway with to also excited could participated who novel potential demonstrated the are on therapies. COPD several have COPD. COPD believe Ensifentrine by of We how therapy. effects a COPD of eager and therapeutic Ensifentrine bronchodilator and patients of not available new therapy challenges June, a pulmonologists

to we webcast, & encourage Events can participate, which you found on were If you Presentations our listen on be the unable site. to to Web

up to treatment patients hospitalized twice-daily this clinical has Ensifentrine of delivered to XX. primarily be via believe day pressurized action Ensifentrine’s to we properties of study of our COVID-XX. the recovered XX of we day University randomized status Ensifentrine XX. or the received and that bronchodilator The at investigate of standard on with coupling the In and evaluated intend longer notice with moderate clearance. at day patients. is for to endpoint COVID-XX focused at clinical of safety hospitalized double-blind if recently primary proportion be receive new is to efficacy compared hospitalized the can to COPD, data lung COVID-XX, Patients developing days. single We added Ensifentrine for the and in XX outcomes, demonstrated While also of the to quarter, may severe and utility care plus treatment Ensifentrine patients care and in in dose metered enhance designed treatment in placebo-controlled that COVID-XX. and Birmingham center both have on continue the patients and XX improve XX of of all its patients improve patients occurs potential evaluate to a stand from milligrams to for of will hospital proceed discharge mucus Ensifentrine before we a at to will patients study inflammation understand pilot placebo. Alabama given with no inhaler of MDI reduced The in A of are, safety to the efficacy trial help trial mechanism initiate until We prior Ensifentrine days a a novel COVID-XX or to two placebo patient IND anti-inflammatory oxygenation,

Secondary supplemental of to treatments study oxygen status, use, endpoints time ventilation, the included in this new requiring recovery, to pandemic. mortality. on you proportion improvements develop forward updating mechanical patients progress for clinical look of and as we We the

from include on abstract the The on Ensifentrine Respiratory significant International first announced XXXX COPD presentations be systems. can statistically Medicine. Tiotropium well clinically Web Conference. Critical dependent of and are the clinical and Journal where that on XXXX, abstracts and that presenting site Care Ensifentrine added pleased are data Thoracic publication, abstracts and and American as Phase the symptom accepted findings ATS Society with American published were We by a nebulized trials improvement six peer-reviewed found in long as demonstrated to January late-breaking dose expands Xb function efficacy in The

at Verona Life to as prepare Ensifentrine. his Xcopri. trials Commercial, and XXXX he Verona in key our than explore Pharma, anti-epileptic the where launched business are we of will now his and developing to for be Vice first COVID-XX, will Pharma, healthcare Verona X the At Phase market, relationships turn Ensifentrine and welcome its Chris to operations We commercial marketing Pharma Marketing results. we We SK our subsidiary analyzing financial commercial and payers over XX team. executing joining experience. Science, I expertise in to Director sales, SK of commence of second who product, developing oversee to in Prior for Chris President, him pre-launch quarter development clinical beginning and welcome with the more commercial a Martin medication years was Mark Executive efficacy Hahn the launch our has Chris instrumental ENHANCE Biopharmaceuticals, will commercial activities. professionals call build As infrastructure. to review

Mark Hahn

Thank you, Dave.

please results, this Turning was as to release also a the which press with that morning, the SEC. issued our filed to refer being is X-K financial

Given sterling. results are Pound our British the U.K., in financial that headquartered are we in

ended from June mentioned. our that the to other that and well Federal the York Bank cash, expected placement balance included XXXX, June Gross $X.XXXX XXX rates to clinical GBP Dave programs dollars, in your Reserve offering convenience, cash million, million have expenses, raised transaction New were proceeds quarter on key and and GBP approximately operations of For proceeds excludes we support be the proceeds or pro were proceeds placement short-term the $XX.X including which $XXX This net investments. based private from or sufficient at for after the GBP million into XX is in to We XX.X buying oversubscribed and these the figures. on equivalents net to translation our fees million, $XXX million million of the deducting financing XXXX. second is and forma a $XXX with noon X cash certain the U.S. is XX, XXXX

for of of million in the costs X.X same of ended ended months of XXXX, loss Phase now XX, value development For $XX ended add-on costs increase increase the an Tiotropium R&D a months to of X and diluted or reported months six development $X.XX months for XXXX, therapy We Finance closure to in Dave. of June compared the or million years is Lower to attributable York associated X.X The GBP six year. is June months the I'll XXXX, million related our decrease to first ended million enhanced represents over General base lower the months loss million, prior tax the or primary per program loss Carolina. X to spending XXXX on GBP primarily a January tax of XXXX, GBP credit as with GBP GBP financial months to based June of clinical Research approximately the primarily Phase million costs Ensifentrine credit by office, of XXXX an XX.X executive read changes XX, costs will GBP $XX ended for compared ended share a coming months increase income expenses our compared million. XX.X months in startup period. finance pence for six offset GBP with finance were increase driver fair tax six a a resulted XX, six development U.K., pounds, of first related credit compared XX, and element income this qualifying to XX.X is in activity for were in of the driven plans. six statement XX six and loss when XX, million in ended in in the attributable decrease and for XX, million X.X GBP costs research expense the diluted during after-tax million. the the million program. six largest In to expenditures as an a change our in of XXXX. expense June ended the credit XXXX, North six of June liability the months compared net This as months the expense on in were million June year for out In back to prior was per compared accelerates six XXXX, an the enhanced believe pence primarily was XXXX. relocation of operations GBP the was the the tax to warrant six important finance comprehensive XX.X This to study administrative call New ended to the June year. XXXX, to that six XX, GBP months Xb in XX, the to R&D XXXX, in June XXXX, less related first the a the of months the which XX, six $X.X this or the of pounds the first X per million, and U.S. share, period June XX.X The XXXX. X.X research smaller of ADS and of of This income turn and our the expenditures. was for XXXX. first

David Zaccardelli

expertise, physician second the commercial-ready executing in pleased company. progress now to our rapidly the up their advance as I team we Ensifentrine Phase that moving our to in and well and like goals are enhanced X to and talents, tremendous the would to made We've I'm clinical turn for open Verona trials a into it Mark. And quarter. questions operator Pharma, thank as on I'll dedication. for answers. Thanks back

Operator

coming question your name. with Please your one the [Operator announcing of ahead Instructions] We from have go line Lucy company's Codrington. question

Lucy Codrington

formulations you. patients of may implied And study, those respiratory COVID then that already just wondering I'm the you've you a intensive it’s chose disclosed? of antibody couple finally, incorporate and interested the from testing, Jefferies. the Codrington going the and to other just the the the Ensifentrine than the to please, MDI during the that to or and other development for? any for are infected have what in study that cash that I long-term into the how of ensure consequences interest, out evaluate a of or X, or was reasoning get MDI behind to whether PD any have Phase questions, including formulation accounted that? trial, symptoms you're that, antigen there, nebulizer is study, Lucy Hi, Secondly, testing other why for runway, Thank so use just just or COVID that indications study, just

David Zaccardelli

with COVID-XX well Thanks very to in dose, Lucy we on very in with the move first hospital maybe as in data those formulation, can in it trials and and and so, the study felt for progressing these reported It think done with then dosage was at that based course, MDI on for I'm format, who and data out this collaboration had I'll dosage felt progressing approach evaluate use the Good this time, this be answer ease-of-use utility forward the for as and third. investigator, hand to so, that patients, questions. COVID-XX. site, effect and of MDI for their recently best additional comfortable an suited to as and the delivery, way. decided know, vitro Mark, into to the clinical, this We you the pleased clinical been have Kathy clinical take questions. I in trial the formulation best single was and the was over

COPD? you Mark, COVID the and the financing want and runway to Now, as of well cash handle proceeds use as

Mark Hahn

for Yes, sure. yes

earmarked but So, really Ensifentrine. that's with the COPD small trial great for amount a of There proceeds cash is as money also relatively been question, for Lucy, of the and are amount nebulized running the an study, offering that's the earmarked from COVID-XX dosing to later. of we would COPD take testing compared we program, or being any to forms activities want the you any as uses but Ensifentrine will the do future at Kathy, look that X? for other COVID in And other engage Phase

Kathy Rickard

with to So the proceeding be are physicians testing every but we most have, it in them the of doing far as COVID mandating care related as Phase X, recommendations time, our done health local and they not what investigators the to for that are discretion. to given countries

in do by available to felt So, done be the won't it time. when be it he investigator, needed done need will they to be when everybody but it, every

Lucy Codrington

to might the patients which [ph]? Okay, [decline] had and infection that before and therefore an screened start have ensure antibodies be long-term just have trials, what about, patients for they will know you

Kathy Rickard

before No, viruses If the you’re at and see screened significant with we time. in probably all expect have from get as our their recovered to don't baseline, any COPD respiratory won't trial they patients, is they’re stable that. trial. virus, This they the be virus. the back differences another aware,

up Also time. of long remember, the how antibodies, really air. whether be last that would time at at don't will be the the really we know information this we the not them antibodies in will useful this screening and for So, state is they

[even] we [ph] this time. So, that's at believe don't

Lucy Codrington

you. Okay, that Thank makes sense.

David Zaccardelli

Lucy. you, Operator? Thank

Operator

company's of from your question go another Tom the Okay, we have with name. coming Shrader. Please your line announcing ahead question

Tom Shrader

Shrader for Tom the is would congratulations This the BTIG. morning. deal. from I add Good

amount have You and a about of provide almost a have right, if on drugs already. have not work. patients, an done question nebulized I they're all incredible is device? the if they're to so complexity, that you a it Is

David Zaccardelli

are COPD you I the sure the trying trial understand to or… Hi, make to Tom, question, I’m referring

Tom Shrader

That's right. yes. Yes,

David Zaccardelli

Yes.

far MDI ENHANCE XX% about or background patients on a that as LAMA the the of XX% X be LABA we're and background on on targeting and Phase DPI therapy will trials, typically or and be will or will can can So, as patients handheld therapy, not device, be either another background patients at also not. given any as at be therapy,

and course MDI/DPI nebulizer into helps. their most the acute the from of sort that's who be nebulizers, they the will I the history patients, study coming or by So, and the mean, products I of patients that received nebulization have experience chronic, have from in even for use, standpoint. a layout of with of may hope past

Tom Shrader

then I have of of not months? point I kind of and for likely exacerbations. just have do to on it's last trial. of they're any signal this out a the you to the okay, exacerbations the get this likely have XX Right, your wondering in patients enrolled had of really trial, number question but know we're sense I'm what

David Zaccardelli

you that? want on comment do to Kathy,

Kathy Rickard

Sure.

are recruiting We are high that patients exacerbated. not

look generally you they're So, more at who normal or studies, for exacerbations year. exacerbation a over one people if looking have

exacerbation doing it's not I for a normal past are shown that. the We about half rate data average exacerbation year. a COPD have an The a think patient,

to patient we're to designed that's we but that look not So the at which going to study we're period months. typical looking being we're six for time, exacerbations, have our assess equipped are specifically of exacerbations study, be to able at over in the

same our exacerbations difference on population, ours, for in exacerbation. not do we're to other some exacerbations, when enough to hopeful studies, of the period. a that able full we'll expect actually and have use able be so, We designed they're from effects studies since analysis they and and show two type show specifically We the to decreasing patient type know in they're patients for similar that of

Tom Shrader

what That's you. want. Thank you. luck. I exactly Thank Good great. That's

Kathy Rickard

Thank you.

Operator

another line question coming have with from ahead Please We of question announcing Liana your Moussatos. the your name. company's go

Liana Moussatos

I'm Wedbush taking for Thank you Securities. my from question.

standard trial, include COVID the care will of the For Remdesivir?

David Zaccardelli

Hi, the be that's physician Liana. prescribed Yes, it what that the would allowed. If will. has patient

Liana Moussatos

treated to account going do are get to how anticipate and you patients And in for, you it? placebo patients to Remdesivir order compare

David Zaccardelli

trial, -- and receiving placebo, expect balanced groups. standard the standard dictate so, I to XX Remdesivir we both will should in a Ensifentrine expect top in it's placebo it's and mean, in will of as think of we I of care, care, and to patient patients we be on out Ensifentrine form, Yes, I not of would again, fall it that be used a XX

Liana Moussatos

Thank you.

David Zaccardelli

Operator?

Operator

and do we question of name. from ahead go line with announcing your have another Yes, Lee. it Joon comes company's the your Please question

Joon Lee

on of been number This forward in a Congrats Joon that go as a funding one, patient, Lee that on questions; hospitalized. hospital financing I Hi. follow-up MDI is removal they're device commented have the more as Securities. MDI have that Truist but felt the well as three of and the choice the the from overhang. the to convenient, might hospital in that hospitals you just

they nebulizer, second the enrollment your a proven undergoing might that X wanted mechanism clinical a And regarding possible that the wouldn't opposed it is has is for then placebo COPD why action. a testing? dual drug the have as because actually question drug arm co-infection the COVID-XX in more patients help both to actually MDI and of still study, is you, of Phase to So, going be having

SARS-CoV-XX mechanism could the I around Phase were Phase strategy the the timing when your help then you. second from if with starting And the pilot just believe, have thoughts the your the and co-infection we'll second and but of having they curious or two that this the what's have more of then X, trial, X? that the find study, Thank is hypothetically, third with there. out SARS-CoV-X, maybe results you those So, to what's

David Zaccardelli

Yes, X, Maybe part. I have her comment, on thanks the Kathy? questions. very and and very she's in Phase over can much with having and thoughts co-infection I'll investigators the last the it MDI turn been because Kathy for on to on the her speaking follow-up directly

Kathy Rickard

Sure.

we and I have data think that see equivalent very confident the DPI mean, is in the we're and the we data So MDI from MDI, with the the equivalent efficacy MDI as I nebulizer. from the our

manner think the small of the investigator pilot which will out study nebulizer that believes a study I from we that's the a by and us the is equivalent point perspective, why to do truly that the hospital this chose in in in them enable for a carry to use in we to the hospitalized study believe patient, the since the in it's easier more, hospital MDI. an and MDI, pilot

I U.S. now new to actually MDI. it's to a use the good MDI. allowing in us have IND have think the We the

us our allowed perspective. that the another to clearance from that experimental to be able So have with MDI, proceed from additional to the FDA

As to COPD clear, if going studies far as are of having COVID. actively co-infections, the they're allowed patients to infection be not be in

personnel that's both from safety these. with protection have of subject all, perspective, we working guard the to First of we're the a and

So disease, anybody tested, be discontinued have be is expected and to and have COVID, the positive to they prove study. they from they'll if will be

patients expectation could control to will that factors perspective, be will allowing from being too So that have the to that there's that active the able think no I from disease many the study. in prevent over study have us allow we

doing So the of intention it. from that's not studies

study other the study the starting time. safety we'll a around but to Phase there, longer will the both X data, Phase, think additional starting than I same in both about same are there's the XX doing start intent them be second The weeks be studies is one because the an question timeframe. the

Joon Lee

Can I follow-up? you ask a

Kathy Rickard

ahead. go Fine,

Joon Lee

and million retrospectively Yes, a anything undetected, who that lack in study, FDA Maybe pre-specified there see analyze science, COVID-XX to sort which like data? says, factor there that the the any go was literature in really confirmed with if COVID infected symptoms. to of are obvious is yes agreed to because literature X for the the are of COVID you there of is says journal the impact because high people XX% that of people the some with U.S. about

for U.S. going you the you're into some that million do it, is virus the asymptomatic patients have and in to to people taking or COVID-XX have end-up plans I the So, that analyze any enrolling assuming data, mean, XX consideration?

Kathy Rickard

the about study Are COPD you versus study? the now talking COVID

Joon Lee

no, COVID-XX the study, maybe study as have or and if and analyze may more to the No, not, no. whether COPD patient results? the looking plans closely data, confounded retrospectively then any you have have

Kathy Rickard

for somebody COPD becomes study, if from treatment, studies, be positive, study. be in again, from the still the will but COVID be they Well, discontinued discontinued the they still but allowed they'll

So, and studies, yes, we could data carry a as in data. allergic do that of lot their we forward, analysis to at look

have certainly we So, that. can a look at

it's group. that If are I high asymptomatic. risk understand COPD be to are they affected patients going that from ones think get are generally not the clear the to they COVID,

clearly they're to are the showing that So, be symptoms. going ones

think I and healthy will not COPD population possibly… asymptomatic relatively people the who to younger, be into going fall and are most people the of are our

Joon Lee

All much. you right, thank very

Kathy Rickard

But that I'm one the of might fact aware or be for two it. positive

Joon Lee

That's you, the congrats yes. thank on it, funding. and Yes,

Kathy Rickard

much. very Thanks

Operator

Please company's coming Thomason. your from ahead of question line go Edward We [Operator a question with the name. have Instructions] your announcing

Edward Thomason

reasonable you. you COVID-XX? MDI for and if tidal or just will Thank theoretically from briefing. the with a flows, issue particularly you whether we on a lot, being flows thought have strategy you do here know questions two focus follow will indications? second dose licensing I a a specific more probably first is due the patients certain with would Thomason in I think on patients hospitalized And being the trial, Edward It's And Ensifentrine license the general tidal the package, and COVID-XX still they're Thanks with for global without either actually but nebulizer with please, question just to formulation was Thank partner if MDI the or formulation, the relation a formulation, update now I may; suit the with poor N+X see you. with to Singer.

David Zaccardelli

Kathy and Hi, part it second. to turn that the take go the Edward, question for and then first of over I'll

far As partners our strategy, States. the for of licensing strategy course United specific outside have we a of as looking partnership

further Ensifentrine and to those be developed Our our intention geographies. for commercialized by is in partner

and in Of large turn get we're territories, course, more this we we going sure, be to so, example, on regionally of are sure or into as and multiple the the for it XXXX in that will China, X Whether EU depend globally making you'd Asia, attention ones our trials. end back expect. year themselves based as the to for on executing it's and Phase the partner

if know, always deal a ways, in is especially You to value that simpler larger multiple provided the many it's covers areas. do

So, we that. will be looking at

the splitting far indication while from it regions that to is I be that. to be listening anything out help start by would As but always commercialization as were approach, possible, development quicker, in and get and find in a difficult if different compound always different different a Ensifentrine indications, quite to clear we countries beneficial

and that's you our So, MDI COVID-XX? overall strategy update, and do Kathy, want to the handle

Kathy Rickard

Sure.

COVID-XX. unlike we are patients, study, recruiting COVID-XX the with the everybody for again remember COPD So,

problems the we're problems, have in ability to effect. tidal be the people not may can COPD who have we were a has patient because lung DPI but which but be pMDI is disease, in have lung function expecting same tidal because using their disperse health limit compromised healthy tidal DPI, to underlying other that who use dry completely with and a devices relatively as lower of individuals, people actually in as their is elements, There'll population that's not who to this volumes, So, particularly powder people far population, we flows, a one the tend if of flow.

enrolling very COVID-XX the that function these were patients in actually will study. pMDI think I well in So,

David Zaccardelli

we more have Operator, for Thanks. question… one maybe time

Edward Thomason

Okay, thank very much. you

David Zaccardelli

queue? somebody Operator, Edward. there question. Thanks, there is in time for one the more Is

Operator

are [Operator be Thank in you. and participant's to announce order them. queue, announce. the and There currently is us. to taking details indeed. details we're somebody to able show with the in waiting will bear Yes, just So, I for Kindly up, their Instructions] we

ahead from comes go Ofer. the your company's question Sharon with name. your Please question announcing our So, of line

Sharon Ofer

This Hi. race. is from Sphera. Sharon Ofer Congratulations on again the

the question of of part used for bronchodilators much as COVID how at care not I'm on So, quite trial, standard the sure COVID are moment.

color some us with not the on So, bronchodilators? the maybe if you maybe be -- prescribed give intentionally patients enrolled can

David Zaccardelli

for hi. on question. Hi, to her give the over maybe I'll Speakers] so turn thoughts Sharon, [Multiple to and… Yes, that, it Yes, thanks Kathy

Kathy Rickard

Sure.

Certainly are So, a of binges world. short-acting shortage patients them so of been lot there decline, yes, we are the lead a available the around has actually that a everything we're demonstrating, being COVID. bronchodilator to because so available. using the there a is much shortage in a bronchodilators drug the It's symptoms can, of

deeper also [ph] and the is yes, thought So, done. from patient, they The helps that you [broncholize] if they clear the easier, breaths, it. being breathe take virus are can

So, think who that it's underlying underlying in lung patients be don't lung certainly, I previous done both have disease, thing important an can do diseases. who and have patients

David Zaccardelli

Great. Kathy. you, Thank

Sharon Ofer

Okay, thank you.

David Zaccardelli

Thank you, Sharon.

Kathy Rickard

Thanks.

David Zaccardelli

Great.

that Ensifentrine. today's I everyone's families, you We I in and -- call. So appreciate stay development during clinical Operator and colleagues your healthy concludes think that continued to on forward your call. our that this updating and time. We for look progress safe participation today's you, support, appreciate hope

Operator

lines. Thank conference, may you. Once your now your this thank you. you today's concludes again, disconnect for Thank Ladies and gentlemen, participation. and you

Verona Pharma (VRNA) 14 Aug 202020 Q2 Earnings call transcript